The DOI matches its Crossref record, with a small difference in title or year; 19 of the 19 references it cites were found in a registry or an index.
Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Abstract
We compared the effect on withdrawal severity and acute outcome of a 25% per week taper of short half-life vs long half-life benzodiazepines in 63 benzodiazepine-dependent patients. Patients unable to tolerate taper were permitted to slow the taper rate. Ninety percent of patients experienced a withdrawal reaction, but it was rarely more than mild to moderate. Nonetheless, 32% of long half-life and 42% of short half-life benzodiazepine-treated patients were unable to achieve a drug-free state. The most difficulty was experienced in the last half of taper. Baseline personality, high Eysenck neuroticism, female sex, and mild-to-moderate alcohol use were found to be more significant predictors of withdrawal severity than the daily benzodiazepine dose or benzodiazepine half-life. These findings suggest that personality factors contribute significantly to the patient's difficulties with gradual benzodiazepine discontinuation of therapeutic doses of benzodiazepines.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical trials evaluating BZD tapering strategies, which typically have relatively fast (e.g., 25% every 1–2 weeks) and inflexible dose reduction schedules, often have high patient dropout.75–77”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [75]
In the citing paper
“Clinical trials that reduced doses at a faster pace tended to have high patient dropout rates.75,76”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [75]
In the citing paper
“Schweizer et al.75 noted that 25% weekly dose reductions was too fast for about half of the participants.”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [75]
In the citing paper
“The population of benzodiazepine patients has been described as a “diagnostically heterogenous group,” which aligns with these results [30,36,40,55,59,65,67].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [65]
In the citing paper
“Some reports have suggested that BZD t 1 ⁄ 2 does not influence withdrawal symptoms (208, 210).”
From Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics (2008) · cites this paper as [208]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory
Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974) · Behavioral Science · doi:10.1002/bs.3830190102 · Cited by 4,604
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Withdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Benzodiazepine withdrawal: an unfinished story.
Ashton, H. (1984) · BMJ · doi:10.1136/bmj.288.6424.1135 · Cited by 291
Gradual Withdrawal of Diazepam after Long-Term Therapy
Tyrer, P., Owen, R., & Dawling, S. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92355-3 · Cited by 271
LENGTH OF TREATMENT WITH ANXIOLYTIC SEDATIVES AND RESPONSE TO THEIR SUDDEN WITHDRAWAL
Covi, L., Lipman, R. S., Pattison, J. H., Derogatis, L. R., & Uhlenhuth, E. H. (1973) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1973.tb04398.x · Cited by 162
Analysis of lorazepam and its glucoronide metabolite by electron-capture gas—liquid chromatography
Greenblatt, D. J., Franke, K., & Shader, R. I. (1978) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)81896-4 · Cited by 99
Cited by
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics
Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01004.x · Cited by 511
Clinical Pharmacokinetics of Alprazolam: Therapeutic Implications
Greenblatt, D. J., & Wright, C. E. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324060-00003 · Cited by 352
Metadata
- Authors
- Schweizer, E.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Schweizer, Edward
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1990-10-01
- Volume
- 47
- Issue
- 10
- Pages
- 908
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2168595696
- Cited by
- 191
- References
- 19
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 2 · 2023: 3 · 2022: 7 · 2021: 5 · 2020: 3 · 2019: 2 · 2018: 8 · 2017: 1 · 2015: 3 · 2014: 5 · 2013: 3 · 2012: 4
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH-08957, MH 34223)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepine dependence, benzodiazepine withdrawal, benzodiazepine tapering, withdrawal severity, personality, alcohol consumption, benzodiazepine discontinuation
- MeSH terms
- Adult, Aged, Anxiety Disorders, Benzodiazepines, Depressive Disorder, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Half-Life, Humans, Male, Middle Aged, Outcome and Process Assessment, Health Care, Panic, Patient Compliance, Personality Inventory, Probability, Substance Withdrawal Syndrome, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper. https://app.cochat.ai/papers/10.1001/archpsyc.1990.01810220024003
- The paper
- Schweizer, E. (1990). Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1990.01810220024003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.